How can we help you?
Effective treatments are an urgent need for brain cancer patients.
We understand that brain cancer does not allow patients the luxury of "waiting."
The team at Brain Cancer Canada is made up entirely of volunteers, as many of us have been directly affected by brain cancer. Our mission is to change outcomes by ensuring that as much as possible of every dollar raised goes directly to research.
We can improve outcomes. Together.
Facts & Figures
9 People
Children and adults, are diagnosed with brain cancer in Canada every day.1 We fight for every single one of them.
120 Different Tumours
While all brain cancers are brain tumours, not all brain tumours are brain cancer. There are approximately 120 different brain tumour types and approximately 1/3 of those are cancerous.
15 - 18 Months
The average survival for the most common and most aggressive adult malignant brain tumour, glioblastoma, is 15-18 months.2
10 - 20%
Of all pediatric brain tumours are Diffuse Intrinsic Pontine Glioma (DIPG). DIPGs are a leading cause of brain tumour deaths in children. 3
2.5 Months
The prevailing treatment protocol for Canadian glioblastoma patients, consistent since 2005, incorporates chemotherapy (Temozolomide) following surgery, paired with radiotherapy, and exhibits a growth in median survival by 2.5 months.4
1 Brain Tumour Registry of Canada. Fact Sheet. Available at: https://braintumourregistry.ca/fact-sheet/ Accessed March 2024.
2 Voisin M, Sasikumar S, Mansouri A, and Zadeh G. Incidence and prevalence of primary malignant brain tumours in Canada from 1992 to 2017: an epidemiologic study. Canadian Medical Association Journal, 2021; 9(4): E973-E979. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580830/#:~:text=In%201992%E2%80%932017%2C%20the%20overall,more%20than%2019%20years%20old. Accessed July 2023.
3 Matthew, R. and Rutka, J. Diffuse Intrinsic Pontine Glioma: Clinical Features, Molecular Genetics, and Novel Targeted Therapies. Journal of Korean Neurosurgery Society, 2018: 61(3): 343-351. https://www.jkns.or.kr/journal/view.php?number=7107. Accessed July 2023.
4 Jia JL, Alshamsan B, Ng TL. Temozolomide Chronotherapy in Glioma: A Systematic Review. Current Oncology. 2023, 30(2), 1893-1902; https://doi.org/10.3390/curroncol30020147. Accessed March 2024.
Turning Corporate Philanthropy into Hope
We invite our corporate partners to explore various ways your organization can support Brain Cancer Canada. Whether through direct contributions, employee matching gift programs, or fundraising initiatives, your involvement can make a significant difference in the lives of those affected by brain cancer. Together, we can create hope, raise awareness, and fund critical research efforts that advance treatment and support for brain cancer patients.
We have watched this charity grow since 2018, with an unwavering commitment towards the integrity to their mission, their transparency of fundraising, and accountability to their work.